Abdullateef M. Busari

Abdullateef M. Busari

Auto-generated profile, based on publicly available information

Abdullateef M. Busari


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2025 in Asian Journal of Microbiology and Biotechnology
Verified
Journal Article
Closed access
OLOlabisi Promise Lawal
Olabisi Promise Lawal
OAOlufemi Adesola Adedayo
Olufemi Adesola Adedayo
SDSokoya Itunuoluwa Dorcas
Sokoya Itunuoluwa Dorcas
OAOlukunle O. Akanbi
Olukunle O. Akanbi
BOBostock Chinecherem Okafor
Bostock Chinecherem Okafor
ABAbdullateef M. Busari
Abdullateef M. Busari
Tuberculosis (TB) still presents a major threat to public health, and accurate diagnosis of tuberculosis, monitoring TB treatment, as well as TB drug resistance are still challenging goals. Research in biomarkers—both host, pathogen pathogen-derived—has led to novel frontiers in the diagnosis and management of TB. These advancements contribute to faster diagnosis, customized treatment plans, and better monitoring of response to therapy. Direct pathogen-based markers, such as M. tuberculosis DNA, lipoarabinomannan (LAM), and mycobacterial proteins, that directly demonstrate infection, have the most potential, particularly in resource-poor settings. Cytokines such as interferon-gamma (IFN-γ) and inflammatory markers, such as C-reactive protein (CRP), are endogenous biomarkers that mirror responses of the immune system and may play a role in the management of treatment, especially in immunocompromised populations, such as patients with HIV. These progresses notwithstanding, the application of a biomarker-centered approach on a large scale remains a major obstacle, due to technical, economic, and regulatory constraints. Furthermore, various performances among the biomarkers in different populations limit clinical utility. Future studies in this area should aim to create point-of-care diagnostics, multi-biomarker panels, and to integrate the device with digital health technology platforms for real-time monitoring. These methods have the potential to substantially improve TB control, particularly in low- and middle-income countries. If current challenges can be overcome and research horizons broadened, biomarker-driven diagnosis and monitoring strategies may have key contributions in global TB control.